THALLOUS CHLORIDE TL 201
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THALLOUS CHLORIDE TL 201 (THALLOUS CHLORIDE TL 201).
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
| Metabolism | Thallous chloride Tl-201 is not metabolized; it decays by electron capture to mercury-201 with a physical half-life of approximately 73 hours. |
| Excretion | Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days. |
| Half-life | Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans). |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Large, approximately 20-30 L/kg. Clinical meaning: Extensive distribution into tissues, particularly myocardium and skeletal muscle. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: myocardial uptake begins within minutes, optimal imaging at 5-10 minutes post-injection. |
| Duration of Action | Myocardial distribution: initial (stress) imaging within 10-15 minutes; redistribution imaging at 3-4 hours. The biologic duration of action for imaging purposes is up to 4 hours, but residual activity persists for days due to long half-life. |
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; thallous chloride is minimally excreted renally. |
| Liver impairment | No dose adjustment required for hepatic impairment; pharmacokinetics unaffected. |
| Pediatric use | 0.035-0.07 mCi/kg (1.3-2.6 MBq/kg) intravenous, minimum dose 0.3 mCi; not recommended for children under 2 years. |
| Geriatric use | No specific dose adjustment; use lowest effective dose to minimize radiation exposure, as in adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for THALLOUS CHLORIDE TL 201 (THALLOUS CHLORIDE TL 201).
| Breastfeeding | Thallous chloride Tl-201 is excreted in breast milk. M/P ratio not established. Milk activity may persist for several days. Breastfeeding should be discontinued for at least 1–2 weeks post-administration to minimize infant exposure. If breastfeeding is essential, pump and discard milk for the recommended period. |
| Teratogenic Risk | Thallous chloride Tl-201 is a radiopharmaceutical. Fetal radiation exposure depends on gestational age. During first trimester, risk of teratogenesis is highest with a threshold around 50–100 mGy. At diagnostic doses (typically <50 mGy), risk is considered low. Second and third trimesters: risk of fetal harm is minimal at diagnostic doses, but theoretical risk of carcinogenesis exists. Avoid use in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to thallous chloride or any component of the formulation"]
| Precautions | ["Radiation exposure risk: cumulative radiation dose should be minimized","Not for use in patients with known hypersensitivity to thallous chloride","May cause fetal harm in pregnant women; assess risk vs benefit","Use caution in patients with renal impairment as clearance may be reduced"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during injection. Perform fetal dose estimation if inadvertent exposure occurs. In rare cases of high radiation exposure, consider fetal ultrasound for growth assessment. |
| Fertility Effects | No known direct effect on fertility at diagnostic doses. High cumulative radiation exposure could theoretically impact gonadal function, but this is not typical with single diagnostic administration. |